- Home
- WIW vs MGTX Comparison
WIW vs MGTX Comparison
Compare WIW & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WIW | MGTX |
|---|---|---|
| Founded | 2004 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 529.9M | 610.1M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | WIW | MGTX |
|---|---|---|
| Price | $8.61 | $7.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $23.83 |
| AVG Volume (30 Days) | 259.2K | ★ 295.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 11.14% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $33,279,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $569.48 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 137.42 |
| 52 Week Low | $8.33 | $4.73 |
| 52 Week High | $9.03 | $9.73 |
Technical Indicators
Market Signals| Indicator | WIW | MGTX |
|---|---|---|
| Relative Strength Index (RSI) | 42.94 | 44.40 |
| Support Level | $8.60 | $7.23 |
| Resistance Level | $8.62 | $8.15 |
| Average True Range (ATR) | 0.06 | 0.33 |
| MACD | -0.01 | -0.04 |
| Stochastic Oscillator | 17.78 | 48.51 |
Price Performance
Historical ComparisonAbout WIW Western Asset Inflation-Linked Opportunities & Income Fund
Western Asset Inflation-Linked Opportunities and Income Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to provide current income. Capital appreciation, when consistent with current income, is a secondary investment objective. The fund operates as a single operating segment, which is an investment portfolio.
About MGTX MeiraGTx Holdings plc
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.